Compare FRNM & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRNM | LTGO |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2024 | 2026 |
| Metric | FRNM | LTGO |
|---|---|---|
| Price | $16.31 | $23.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 892.0K | 283.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.97 | $17.22 |
| 52 Week High | $17.10 | $25.93 |
| Indicator | FRNM | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 84.77 | 61.51 |
| Support Level | $9.97 | $21.26 |
| Resistance Level | N/A | $25.47 |
| Average True Range (ATR) | 0.84 | 1.87 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 99.29 | 44.44 |
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.